Collection: Men's Outerwear
Stay cozy and make an impact with our selection of jackets and outerwear, designed to keep you warm through fall and winter while supporting an important cause. From snug fleeces and versatile hoodies to lightweight jackets and insulated outerwear, our collection has everything you need to face the cooler seasons in style. Each piece combines premium quality with functional design—crafted for comfort, durability, and a perfect fit for any occasion, whether you’re braving the outdoors or layering up for daily wear.
Profits from this collection go to Sky Foundation, a non-profit that funds pancreatic cancer research.. By choosing outerwear from this collection, you’re not only investing in your warmth but also helping to bring hope and resources to those affected by pancreatic cancer.
Find your next layer of warmth and purpose here, and wear your support proud.

-
Men's Columbia Soft Shell Jacket (Embroidered Purple Ribbon)
Regular price From $149.00 USDRegular priceUnit price / per -
Men's Heavy Blend Zip Hoodie (Embroidered Purple Ribbon)
Regular price From $46.50 USDRegular priceUnit price / per -
Men's Lightweight Zip Hoodie (Embroidered Purple Ribbon)
Regular price From $54.00 USDRegular priceUnit price / per -
Men's Quarter Zip (Embroidered Purple Ribbon)
Regular price From $63.50 USDRegular priceUnit price / perSold out -
Men's Quarter Zip (Embroidered Sky Logo)
Regular price From $63.50 USDRegular priceUnit price / perSold out -
Men's Wind Breaker Jacket (Embroidered Purple Ribbon)
Regular price From $64.00 USDRegular priceUnit price / per
Latest News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...